Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Intra-arterial Vasospasm Trial
NCT01996436 · Peng Roc Chen, MD · PHASE4 · terminated · last registry update 2025-05-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow enrollment” | – | Registry record, Peng Roc Chen, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-16Results posted on the registry: University of California, Irvine, Nortriptyline + Topiramate + Verapamil + Paroxetine (NCT04404439)
- 2025-12-24Phase 3 first posted: University Hospital, Basel, Switzerland, DEB-DoxNic-TACE + current standard of care (NCT07302919)
- 2025-11-10Results posted on the registry: Wake Forest University Health Sciences, Calcium pre-treatment (NCT05661942)
- 2025-10-30Also stopped (terminated): Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-16Results posted on the registry: Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-14Results posted on the registry: Vanderbilt University Medical Center, diltiazem (NCT06534671)
- 2025-10-10Results posted on the registry: Mersin Medicalpark Hastanesi, Verapamil (NCT06447688)
- 2025-09-22Also stopped (terminated): Viatris Innovation GmbH, ACT-334441 2 mg + ACT-334441 4 mg (NCT02479204)
- 2025-02-25Results posted on the registry: Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-25Also stopped (terminated): Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-13Phase 3 first posted: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., SYH9056 + Levamlodipine (NCT06771245)
- 2024-12-27Results posted on the registry: Corewell Health South, Oral + Intravenous drug (NCT05391893)
- 2024-12-05Phase 3 first posted: Rashid Latif Medical College, Adenosine + Verapamil Injection (NCT06717685)
- 2024-11-27Results posted on the registry: Jaeb Center for Health Research, verapamil 120mg tablet + placebo (NCT04233034)
- 2024-11-07Phase 3 first posted: Yonsei University, BP lowering drugs (nicardipine, labetalol, urapidil) + BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil) (NCT06677970)
- 2024-10-24Also stopped (withdrawn): Stephen Ruedrich, Valbenazine Oral Capsule (NCT06107829)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision